CAS: 36589-58-9; Sodium Propane-1,3-Disulfonate

该化合物是一种化学化合物,其特点是其全氟辛烷磺酸功能组群,是一种1,3-丙烷基硫酸的二钠盐,这意味着它含有每种酸分子的两种钠离子.该化合物一般是一种在水中溶解的白色晶状固体,在各种应用中,包括作为一种缓冲剂和生物化学研究中都有用.全氟辛烷磺酸组的存在具有很强的酸性,有助于其与蛋白质和其他生物分子进行互动.此外,其结构允许在药物以及清洁剂和表面活性剂的配制中潜在应用.一般认为,该化合物在标准条件下稳定,但与许多全氟辛烷磺酸一样,由于酸性,应当谨慎处理.总体来说,1,1,3-丙烷基硫酸二钠因其溶解性和在水环境中的再活性而具有价值.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号109-64-8 1,3-二溴丙烷 | CAS号20686-91-3 1,3-Propanedisu...

合成工艺路线路线简述

    专利信息


    专利号:US-9751877-B2
    优先权日:2012-09-21
    标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
    发明人:PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
    权利人:PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-9771379-B2
    优先权日:2015-09-24
    标题:N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides
    发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS
    权利人:PFIZER
    摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nwherein the variables R 1 , R 2 , R 3 , R 4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:WO-2012172449-A1
    优先权日:2011-06-13
    标题:Lactams as beta secretase inhibitors
    发明人:BRODNEY MICHAEL AARON
    权利人:PFIZER; BRODNEY MICHAEL AARON
    摘要:Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. The compound of formula I is useful as beta secretase inhibitor for use in the treatment of Alzheimer's and other neurodegenerative and/or neurological disorders.

    专利号:US-2016229847-A1
    优先权日:2013-10-04
    标 题:Novel bicyclic pyridinones as gamma-secretase modulators
    发明人:PETTERSSON MARTIN YOUNGJIN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; JOHNSON DOUGLAS SCOTT; KAUFFMAN GREGORY WAYNE; O'DONNELL CHRISTOPHER WILLIAM; PATEL NANDINI CHATURBHAI; STEPAN ANTONIA FRIEDERIKE; STIFF CORY MICHAEL; SUBRAMANYAM CHAKRAPANI; TRAN TUAN PHONG; VERHOEST PATRICK ROBERT
    权利人:PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-9067934-B2
    优先权日:2011-03-31
    标题 :Bicyclic pyridinones
    发明人:PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; FISH BENJAMIN ADAM; GREEN MICHAEL ERIC; MULLINS PATRICK BRADLEY; STIFF CORY MICHAEL; TRAN TUAN PHONG; NAVARATNAM THAYALAN
    权利人:PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-8962616-B2
    优先权日:2012-05-04
    标 题:Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
    发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; BECK ELIZABETH MARY; DAVOREN JENNIFER ELIZABETH; O'NEILL BRIAN THOMAS
    权利人:PFIZER
    摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014 Oct 29;6:369-77. doi: 10.2147/CLEP.S39981. eCollection 2014. Review.
    2: Wang P, Ding K. Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease. Protein Pept Lett. 2014;21(10):1048-56. Review. doi: 10.2147/IJNRD.S19165. Epub 2012 Feb 24.
    4: Martínez-Valle F, Gironella-Mesa M, Solans-Laqué R. [New trends in the treatment of amyloidosis]. Med Clin (Barc). 2012 May 26;138(15):667-72. doi: 10.1016/j.medcli.2011.09.032. Epub 2011 Dec 22. Review. Spanish. doi: 10.1159/000314795. Epub 2011 Jan 20. Review. Polish. doi: 10.1007/s00292-009-1140-5. Review. German. doi: 10.1517/14656566.9.12.2175 . Review. Italian. Epub 2007 Sep 18. Erratum in: Amyloid. 2007 Dec;14(4):325. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2349-60. Epub 2007 Jan 26. Review. French.

    合成参考文献


    参考文献:10.1007/s10165-008-0035-2|10.3109/s10165-008-0035-2
    摘要:Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2008;18(2):109–18. doi: 10.1007/s10165-008-0035-2.
    参考文献:10.1007/s10067-008-0875-3
    摘要:Perry ME, Stirling A, Hunter JA. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin Rheumatol. 2008 Jul;27(7):923–5. doi: 10.1007/s10067-008-0875-3.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知